Related Experiment Video
Updated: Jan 12, 2026
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
Three decades of radiotherapy advancements for pediatric ependymoma
Thomas E Merchant1, Vijay Ramaswamy1, Jeffrey Leonard1
1Chair, Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, United States.
Insights
Radiotherapy has significantly improved pediatric ependymoma treatment over 30 years. Advances like proton therapy and reirradiation offer better outcomes and reduced complications for children.
Area of Science:
- Pediatric oncology
- Radiation oncology
- Neuro-oncology
Background:
- Over 30 years, radiotherapy has transformed pediatric ependymoma treatment.
- Early protocols established immediate post-operative radiotherapy efficacy.
- Conformal photon and proton therapy advanced tumor targeting and normal tissue sparing.
Purpose of the Study:
- To review advancements in radiotherapy for pediatric ependymoma.
- To highlight challenges in treating residual or recurrent disease.
- To emphasize the need for data from clinical trials to refine strategies.
Main Methods:
- Review of radiotherapy protocols (RT1, ACNS0121) and techniques (photon, proton therapy).
- Discussion of factors influencing radiotherapy planning (location, age, molecular features).
- Exploration of imaging and molecular staging advancements.
Main Results:
- Radiotherapy has improved tumor control and reduced complications in pediatric ependymoma.
- Proton therapy is preferred in developed nations for its tissue-sparing benefits.
- Reirradiation shows promise for recurrent ependymoma with surgery and multidisciplinary care.
Conclusions:
- Continued progress relies on leveraging clinical trial data to refine treatment strategies.
- Addressing cognitive outcomes is a critical area for research.
- Future research will focus on molecular risk stratification and systemic therapy integration.
Abstract:
Over the past 30 years, advancements in radiotherapy have transformed the treatment of pediatric ependymoma, improving tumor control and reducing treatment-related complications. Early protocols, such as RT1 and ACNS0121, demonstrated the efficacy of immediate post-operative radiotherapy, particularly for children as young as 12 months, setting benchmarks for modern treatment strategies. The introduction of conformal photon therapy revolutionized tumor targeting by minimizing radiation exposure to surrounding normal tissues, while proton therapy has emerged as the preferred modality in developed countries due to its superior normal tissue-sparing properties. Despite these advances, long-term comparative data between photon and proton therapy remains limited. Critical factors in radiotherapy planning include tumor location, patient age, molecular features, and the potential for neuraxis dissemination. Advances in imaging, such as high-resolution MRI and emerging molecular staging techniques, have enhanced precision in treatment planning and risk stratification. However, challenges persist for patients with residual or recurrent disease. Reirradiation has emerged as a promising option for relapse, demonstrating high rates of tumor control and low risks of complications when combined with timely surgical intervention and multidisciplinary care. This chapter highlights the importance of leveraging data from three separate clinical trials to refine treatment strategies and address cognitive outcomes, which have been identified as a major area of clinical importance and research. Future trials are expected to explore molecular risk stratification and the integration of systemic therapies alongside radiotherapy to optimize outcomes, ensuring continued progress in the care of children with ependymoma.
